Morphic Holding, Inc. (MORF)
Market Cap | 1.46B |
Revenue (ttm) | n/a |
Net Income (ttm) | -161.25M |
Shares Out | 50.09M |
EPS (ttm) | -3.50 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 244,186 |
Open | 29.44 |
Previous Close | 29.33 |
Day's Range | 28.85 - 29.85 |
52-Week Range | 19.35 - 63.08 |
Beta | 1.48 |
Analysts | Buy |
Price Target | 54.40 (+86.75%) |
Earnings Date | Apr 25, 2024 |
About MORF
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the... [Read more]
Financial Performance
In 2023, MORF's revenue was $521,000, a decrease of -99.26% compared to the previous year's $70.81 million. Losses were -$152.10 million, 157.6% more than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for MORF stock is "Buy." The 12-month stock price forecast is $54.4, which is an increase of 86.75% from the latest price.
News
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
MORF ends 1Q24 with $659 million, cash into 2H27; phase 2b study of MORF-057 in UC continues on target; anticipate GARNET phase 2 in Crohn's to begin 2Q
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding,...
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding,...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding,...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, ...
Ademi LLP Investigates Claims of Securities Fraud against Morphic Holding, Inc.
MILWAUKEE , April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Morphic (NASDAQ: MORF). The investigation results from inaccurate statements Morphic may h...
Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)---- $MORF #classaction--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Morphic Holding, Inc. (“Morphic...
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory Diseases Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory Disease...
Morphic to Participate in March Investor Conferences
WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chron...
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023
MORF ends '23 with $700 million, cash into 2H27; MORF-057 EMERALD-2 UC trial enrolling on target; to begin Ph 2 GARNET trial of 057 in Crohn's disease 1H24
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holdin...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Morphic Holding, Inc. (“Morphic” or the “Company”) (NASDAQ: MORF) investors concerning the Compan...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Morphic Holding, ...
The Law Offices of Frank R. Cruz Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Morphic Holding, Inc. (“Morphic” or the “Company”) (NASDAQ: MORF) on behalf of investors concerning the Com...
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave- WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology co...
Robbins LLP Reminds MORF Investors that it is Investigating Morphic Holdings, Inc. on Behalf of Investors
SAN DIEGO--(BUSINESS WIRE)---- $MORF #MorphicHoldingInc--Robbins LLP Reminds MORF Investors that it is Investigating Morphic Holdings, Inc. on Behalf of Investors.
Morphic Holding, Inc. Reminder: Robbins LLP is Investigating MORF on Behalf of Investors
SAN DIEGO--(BUSINESS WIRE)---- $MORF #MorphicHoldingInc--Morphic Holding, Inc. Reminder: Robbins LLP is Investigating MORF on Behalf of Investors.
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)
NEW YORK , Oct. 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or the "Company") (NASDAQ: MORF). Such investors are advised t...
Morphic Holding Investigation: Johnson Fistel Encourages Shareholders with Losses to Contact the Firm Regarding Investigation
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Morphic Holding, Inc. (NASDAQ: MORF), any of its executive officers, or oth...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 16, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holdin...
Morphic Holding SHAREHOLDER ALERT: Johnson Fistel Encourages Morphic Holding Shareholders with Losses to Contact the Firm Regarding Investigation
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Morphic Holding, Inc. (NASDAQ: MORF), any of its executive officers, or oth...
MORF INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
SAN DIEGO , Oct. 13, 2023 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Morphic Holding, Inc. (NASDAQ...
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ch...
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding...